SynthesisBMC cardiovascular disorders2026
Cardiovascular outcomes and adverse drug reactions associated with the use of ezetimibe in combination with a statin in diabetes mellitus patients with higher risk for myocardial infarction: a meta-analysis.
Synthesis in BMC cardiovascular disorders, 2026. The graph read 1 number from its abstract, feeding 2 cells of the map, but none could be read as for or against, so it casts no vote. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Read, but not usablea number the graph found but could not read as for or against
Results of this analysis showed that when the cardiovascular outcomes were compared, major adverse cardiovascular events (MACEs) were significantly lower in the ezetimibe-statin group with RR: 0.90, 95% CI: 0.82 - 0.99; P = 0.02.
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Other lipid agents×cardiovascular events
No readable resultOpen on the map →What to test next →10 readable studies in this cell: 5 favour the treatment, 5 find no difference, 0 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
Statins×cardiovascular events
No readable resultOpen on the map →What to test next →30 readable studies in this cell: 18 favour the treatment, 11 find no difference, 1 favour the comparator.
This paper's own estimate is on a different scale from the rest of the cell, so it is not drawn here.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The marked sentences are the ones the graph read a number from.
backgroundIt is well known that diabetes mellitus (DM) is an important risk factor for the development of cardiovascular diseases (CVD). Ezetimibe, an inhibitor of cholesterol absorption, is now a second-line lipid-lowering therapy with apparently more benefits. Ezetimibe can be used in addition to a statin in order to further reduce low density lipoprotein (LDL) levels. In this analysis, we aimed to systematically compare the cardiovascular outcomes and the adverse drug reactions associated with the use of ezetimibe in combination with a statin versus statin monotherapy in type 2 DM patients with higher risk for myocardial infarction (MI).
methodsWeb of science (WOS), MEDLINE, Clinicaltrials.gov, EMBASE, Google scholar and the Cochrane database were searched for studies comparing endpoints with ezetimibe-statin combination versus statin monotherapy in DM patients with higher cardiovascular risks. Major cardiovascular outcomes, stroke and adverse drug events were the endpoints in this study. The statistical analysis was carried out by the RevMan 5.4 software. Risk ratios (RR) with 95% confidence intervals (CI) were used to represent the data following statistical analysis.
resultsTwelve studies with a total number of 25,591 DM participants (12,478 assigned to ezetimibe-statin and 13,113 assigned to statin monotherapy) with higher risk for MI were included in this analysis. Results of this analysis showed that when the cardiovascular outcomes were compared, major adverse cardiovascular events (MACEs) were significantly lower in the ezetimibe-statin group with RR: 0.90, 95% CI: 0.82 – 0.99; P = 0.02. However, all cause mortality, cardiovascular death, MI, atrial fibrillation, hospitalization for unstable angina, and hospitalization for heart failure were similar. The adverse drug events were also compared without any significantly different result.
conclusionsOur analysis showed that ezetimibe-statin combination was associated with a significantly lower risk of MACEs without increasing the risk of adverse drug reactions when compared to statin monotherapy in these DM patients with higher risk for MI. However, due to several limitations, and the influence of data from observational studies, this hypothesis must be cautiously considered until further larger trials are carried out to confirm the results.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.